Literature DB >> 1975036

Liver transplantation across ABO blood group barriers.

J Gugenheim1, D Samuel, M Reynes, H Bismuth.   

Abstract

In a study of 234 liver transplants the 2-year graft survival for ABO-compatible elective (80%) or emergency (76%) liver transplants was significantly higher than that for ABO-incompatible emergency liver transplants (30%). The low survival of ABO-incompatible liver allografts was therefore not related to the emergency conditions. Among 17 patients who received ABO-incompatible liver allografts, primary humoral rejection, with haemorrhagic infiltration of portal tracts and deposition of IgM and fibrinogen on sinusoidal and endothelial cells, developed in 6. Other disadvantages of ABO-incompatible liver allografts were significantly higher frequencies of severe rejection crises, arterial thrombosis, and cholangitis. However, the 1-year survival rate of the patients who received ABO-incompatible grafts was 66%, so the use of ABO-incompatible liver grafts is justifiable in emergencies, when no other donor is available; such transplants may help to save the patient, even at the cost of retransplantation in half of the cases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1975036     DOI: 10.1016/0140-6736(90)92082-s

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  34 in total

Review 1.  B cells and transplantation tolerance.

Authors:  Allan D Kirk; Nicole A Turgeon; Neal N Iwakoshi
Journal:  Nat Rev Nephrol       Date:  2010-08-24       Impact factor: 28.314

2.  Liver transplantation: Evading antigens-ABO-incompatible liver transplantation.

Authors:  Ali Zarrinpar; Ronald W Busuttil
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-11-18       Impact factor: 46.802

3.  Internal bioartificial liver with xenogeneic hepatocytes prevents death from acute liver failure: an experimental study.

Authors:  V Roger; P Balladur; J Honiger; M Baudrimont; R Delelo; A Robert; Y Calmus; J Capeau; B Nordlinger
Journal:  Ann Surg       Date:  1998-07       Impact factor: 12.969

4.  Interventional radiology: management of biliary complications of liver transplantation.

Authors:  Nishita Kothary; Aalpen A Patel; Richard D Shlansky-Goldberg
Journal:  Semin Intervent Radiol       Date:  2004-12       Impact factor: 1.513

5.  Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch.

Authors:  H R Doyle; I R Marino; F Morelli; C Doria; L Aldrighetti; J McMichael; J Martell; T Gayowski; T E Starzl
Journal:  Ann Surg       Date:  1996-08       Impact factor: 12.969

6.  The reduction rate of serum C3 following liver transplantation is an effective predictor of non-anastomotic strictures.

Authors:  Shuang Liu; Tonghai Xing; Tao Sheng; Shouwen Yang; Li Huang; Zhihai Peng; Xing Sun
Journal:  Hepatol Int       Date:  2014-03-06       Impact factor: 6.047

7.  ABO-incompatible deceased donor pediatric liver transplantation: Novel titer-based management protocol and outcomes.

Authors:  Krupa R Mysore; Ryan W Himes; Abbas Rana; Jun Teruya; Moreshwar S Desai; Poyyapakkam R Srivaths; Kimberly Zaruca; Andrea Calvert; Danielle Guffey; Charles G Minard; Eda Morita; Lisa Hensch; Michael Losos; Vadim Kostousov; Shiu-Ki Rocky Hui; Jordan S Orange; John A Goss; Sarah K Nicholas
Journal:  Pediatr Transplant       Date:  2018-08-02

8.  ABO-incompatible living donor liver transplantation without graft local infusion and splenectomy.

Authors:  Seung Duk Lee; Seong Hoon Kim; Sun-Young Kong; Young-Kyu Kim; Soon-Ae Lee; Sang-Jae Park
Journal:  HPB (Oxford)       Date:  2014-01-28       Impact factor: 3.647

9.  Adult Living Donor Liver Transplantation with ABO-Incompatible Grafts: A German Single Center Experience.

Authors:  Armin D Goralczyk; Aiman Obed; Andreas Schnitzbauer; Axel Doenecke; Tung Yu Tsui; Marcus N Scherer; Giuliano Ramadori; Thomas Lorf
Journal:  J Transplant       Date:  2010-02-03

10.  ABO incompatible liver transplantation as a bridge to treat HELLP syndrome.

Authors:  Kathleen Connor; Raymond A Rubin; Roshan Shrestha; Mark Johnson; Marty Sellers; Brad Butler
Journal:  Gastroenterol Res Pract       Date:  2009-09-28       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.